Various caffeic acid derivatives were synthesized, and their effects on 5-lipoxygenase (5-LO), 12-lipoxygenase (12-LO) and prostaglandin (PG) synthase activities were investigated. Among them, caffeic acid octyl amide (5) and 1-(3, 4-dihydroxyphenyl)-1-octen-3-one (11) showed very potent inhibitory activities toward 5-LO with IC50 values of 4.2×10-8 and 3.5×10-8 M, respectively. They were very selective inhibitors for 5-LO. Compound 11 showed noncompetitive inhibition, and the two adjacent hydroxy groups attached to the benzene ring, as well as the hydrophobic alkyl side chain, were required for its strong binding to 5-LO.
New phenolic cinnamic acid derivatives as selective COX-2 inhibitors. Design, synthesis, biological activity and structure-activity relationships
作者:Daniela Ribeiro、Carina Proença、Carla Varela、João Janela、Elisiário J. Tavares da Silva、Eduarda Fernandes、Fernanda M.F. Roleira
DOI:10.1016/j.bioorg.2019.103179
日期:2019.10
potent anti-inflammatory agents, with fewer gastrointestinal side effects. In this work, a new series of cinnamic acid derivatives, namely hexylamides, have been designed, synthesized and evaluated in human blood for their inhibitory activity of COX-1 and COX-2 enzymes. From this, newstructure-activityrelationships were built, showing that phenolic hydroxyl groups are essential for both COX-1 and COX-2
purpose of this study was to examine the neuroprotective effects of caffeicacid hexyl (CAF6) and dodecyl (CAF12) amidederivatives on the early stage of retinopathy in streptozotocin‐induced diabetic rats. Animals were divided in five groups (n=8/group); one group consisted of non‐diabetic rats as control, while the other four were diabetic animals either non‐treated or treated with CAF6, CAF12 or resveratrol
METHOD FOR ANTI-SKIN AGING USING CAFFEAMIDE DERIVATIVE
申请人:CHINA MEDICAL UNIVERSITY
公开号:US20150010484A1
公开(公告)日:2015-01-08
A method for anti-skin aging, especially for anti-skin photo-aging in a subject is provided. The method comprising administering to the subject an effective amount of an active component selected from the group consisting of a caffeamide derivative of formula (I), a pharmaceutically acceptable salt of the caffeamide derivative, and a combination thereof:
wherein A is H or an alkyl; B is —[CH2]
m
—; m is an integer ranging from 0 to 10; R1 is H, an optionally substituted phenyl, an optionally substituted pyridyl, —OH, or —OCH
3
; or, N, A, B, and R1 together form an optionally substituted pyrrolyl or piperidyl.